Physician profile
Dina B Pearson
NPI 1326250523
$1,656.99
in general payments reported to CMS, 2019-2025
26 companies · $896 in 2025
The $896 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $65.83 · 2022: $146 · 2023: $22.38 · 2024: $245 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $88.13 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.98 |
| Education | $88.13 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.92 | 2019-2025 | |
| Sequel Med Tech, LLC | $184.66 | 2025 | Twiist |
| Soleno Therapeutics, INC. | $153.41 | 2025 | Vykat Xr |
| Novo Nordisk INC | $122.21 | 2019-2025 | Sogroya |
| Neurocrine Biosciences, INC. | $95.14 | 2025 | |
| Insulet Corporation | $89.62 | 2019-2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $89.07 | 2019-2025 | Ultomiris |
| Pfizer INC. | $88.69 | 2024-2025 | |
| Beta Bionics, INC. | $72.73 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $71.12 | 2022-2025 | Skytrofa |
| Azurity Pharmaceuticals, INC. | $63.60 | 2024-2025 | Triptodur |
| Calliditas Therapeutics US INC. | $56.03 | 2025 | Tarpeyo |
| Abbott Laboratories | $49.95 | 2025 | Freestyle Insulinx |
| Tolmar, INC. | $45.94 | 2024-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $39.89 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $39.49 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $36.40 | 2019-2020 | |
| Sandoz INC. | $27.11 | 2025 | Omnitrope |
| Apellis Pharmaceuticals, INC. | $19.53 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $18.81 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $18.15 | 2022 | |
| Lilly USA, LLC | $15.57 | 2019 | |
| Eton Pharmaceuticals, INC. | $15.19 | 2025 | Nitisinone, Betaine Anhydrous, Carglumic Acid |
| Jazz Pharmaceuticals INC. | $14.35 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.33 | 2019 | |
| Zealand Pharma US, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.